Inovio Pharmaceuticals (INO) jumps 18% and here’s why
- Shares of Inovio Pharmaceuticals closed up 18% on Wednesday after Jim Cramer mentioned the vaccine maker an on his Mad Money show yesterday.
- The company is developing a vaccine named INO-4800 and has entered a phase 1 clinical trial earlier this month
- Data from Inovio’s study will be released late this summer and is tempting for investors trying to capitalize on the COVID-19 vaccine demand.
Though the company may seem promising, there is still a lot of risk at hand. First, there is no telling if the vaccine could produce antibodies that will protect patients making it a viable vaccine. On top of this, the cost to manufacture the vaccine is uncertain which means there is no telling how many Inovio will be able to sell. With a market cap of $1.7 billion, Inovio isn’t particularly expensive, and if the company sees good results regarding the clinical trial this stock could make investors rich. Overall, the stock is something to keep an eye out for but nothing to throw all of your money in. Approach it more as a gamble than an investment.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.